Navigation Links
New Engineered Drug Shows Promise in Treating Lymphocytic Leukaemia

A recent research has found that a new type of engineered drug may have the potential to treat chronic lymphocytic leukaemia.

The study by researchers at the Ohio State University Comprehensive Cancer Center was published online in the journal Blood.

The research has established that an engineered drug candidate is promising in treating lymphocytic leukemia in both test tube and early animal tests.

The agent represents a new class of agents called small modular immunopharmaceuticals. This agent, which is called CD37-SMIP, targets a protein called CD37 on the surface of these leukemia cells.

The study shows that the agent can successfully attach to the protein on the leukemia cells and destroy them. It works both by activating the cells' self-destruction and by causing a particular class of immune cells to attack them.

In an animal model, the agent worked uniformly over and above the drug rituximab, now routinely used to treat chronic lymphocytic leukemia (CLL) patients. Rituximab targets a different protein on leukemia cells.

"Our findings have significant implications for the treatment of CLL and related malignancies," says principal investigator John C. Byrd, director of the hematologic malignancies program at Ohio State 's James Cancer Hospital and Solove Research Institute.

Overall, Byrd says, "the findings point out that this could be an effective agent for treating CLL and other malignancies, such as non-Hodgkin's lymphoma and acute lymphoblastic leukemia when they have expression of the CD37 protein."

The laboratory portion of the study used CLL cells from patients, laboratory-grown non-Hodgkin's lymphoma cells and acute lymphocytic leukemia cells.

This research showed that the agent kills leukemia cells directly by triggering their self-destruction through the process of apoptosis.

The study also found that thi s self-destruction happens differently from how other drugs cause apoptosis. Most drugs cause cells to self-destruct by triggering a cell mechanism that requires enzymes called caspases. This new agent, however, works through a mechanism that does not call for caspases.

"This is exciting because it means that this agent may benefit patients who are resistant to other CLL drugs," says co-author Natarajan Muthusamy, a research scientist with Ohio State's Comprehensive Cancer Center. "It also suggests that it might work well in combination with other drugs, as well as alone."

The findings also show that after the agent joins with the cancer cells, it attracts immune cells called natural killer cells, which also devastate the leukemia cells.


'"/>




Related medicine news :

1. Regulators Object Drug Produced from Genetically Engineered Farm Animals
2. Engineered Tissue Implants benefited Knee Injured patients
3. Indian American have Genetically Engineered Edible Cottonseed
4. USDA Gives Go-Ahead to Market Controversial Genetically Engineered Rice, LL601
5. Xylitol To Be Produced By Genetically Engineered E. Coli
6. Genetic-Engineered Cows Resist Mad Cow Disease
7. Researchers Explore the Effect of Engineered Immune Cells on HIV
8. Tissue Engineered Scaffolding Allows Reproduction of Cartilage Tissue
9. Experimental treatment for Ebola Virus Shows promising results in mice
10. New Prostate Cancer Vaccine Shows Promise
11. Ebola Treatment Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... Durham, NC (PRWEB) , ... March 30, 2017 ... ... professionals, will host the live audio conference “ Preventing Hospital Readmissions Through Discharge ... April 12, 2017 at 1:00 pm ET. This conference discusses strategies to prevent ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS ... Medical Center will serve as the official title sponsor of the Baltimore Women’s Classic, ... 2017, thousands of women will walk or run the course around the Baltimore Inner ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy ... attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. ... recognized as the visionary leader in the training of physicians, scientists, and members ...
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 ... "Intraoperative Neuromonitoring (IONM) Market Size & Forecast By Type (Insource ... - 2025" report to their offering. ... The global Intraoperative ... by 2025. The intraoperative neuromonitoring market is anticipated to witness ...
(Date:3/29/2017)... March 29, 2017 Global intravenous (IV) iron and ... by 2021, growing at a CAGR of 5%. ... a doctor to treat anemia or other iron deficiencies. Oral ... the body. However, in some cases, oral administrations are not ... intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... 29, 2017 Today, CVS Health officials (NYSE: ... , Department of Public Health Director Gerd Clabaugh ... in announcing the availability of the opioid overdose-reversal medicine ... Iowa.  CVS Health has established a standing order with physicians ... to expand access to the medication in the state.   ...
Breaking Medicine Technology: